LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

LLY

984

+0.74%↑

JNJ

243.34

-0.1%↓

ABBV

223.44

-1.39%↓

NVS

153.7

-0.31%↓

AZN

190.14

-0.92%↓

Home・Aandelen Lijst・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Open

SectorGezondheidszorg

57.89 -0.53

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

56.78

Max

58.65

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -105M
Winstmarge	-867.293
Werknemers	358
EBITDA	-15M -104M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+25.83% upside

Dividenden
By Dow Jones
Volgende Winsten	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.9B 5.2B
Vorige openingsprijs	58.42
Vorige sluitingsprijs	57.89

Nieuwssentiment

By Acuity

30%

70%

68 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.81 / 38.24 Steun & Weerstand

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 mrt 2026, 16:12 UTC

Belangrijke Marktbewegers

Xenon Pharmaceuticals Shares Surge on Positive Study Data for Azetukalner

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

25.83% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 74.29 USD 25.83%

Hoogste 100 USD

Laagste 50 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Gebaseerd op 19 analisten die aandelenratings hebben gegeven aan Xenon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

68 / 351 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.